New needle-free intranasal aerosol adrenaline administration device called Neffy, 2mg, has 30 month shelf life, and FDA and European approval (EUR Neffy). Not yet available in UK, but expected in Summer 2025. Administered via the nose, has absorption enhancer (reduces mucus viscosity).
Administer dose of 2mg adrenaline (epinephrine) from 30kg body weight, 1mg device for 15-30kg (planned for children) and device comes as two single-dose nasal sprays in a kit. Stored at room temperature, it is smaller than Epipen, so easier to carry. Adrenaline (Epinephrine) bioavailability via this easy-to-administer device is superior to Epipen and IM adrenaline, with sustained systolic and diastolic BP improvement . Second dose if necessary administered into same nostril as opposed to IMI adrenaline administered into opposite thigh (if second dose is necessary).
Reference: https://www.bmj.com/content/386/bmj.q1789
